×
Newsmax TV & Webwww.newsmax.comFREE - In Google Play
VIEW
×
Newsmax TV & Webwww.newsmax.comFREE - On the App Store
VIEW
Tags: insomnia | sleep | pill | drug | suvorexant | merck | fda

FDA Rejects Merck's Insomnia Drug Suvorexant

Monday, 01 July 2013 02:26 PM

Merck & Co Inc. said the U.S. Food and Drug Administration rejected the company's experimental insomnia drug, citing safety issues.

In a complete response letter to the company, the FDA said the safety data of the drug do not support approval, and advised that lower doses of the medicine should be made available before an approval.
 
The efficacy of the drug, suvorexant, was established at doses of 10 mg to 40 mg in adults, the FDA said, adding that 10 mg should be the starting dose for most patients.

© 2022 Thomson/Reuters. All rights reserved.


Health-Wire
Merck said the U.S. Food and Drug Administration rejected the company's experimental insomnia drug, citing safety issues.
insomnia,sleep,pill,drug,suvorexant,merck,fda
89
2013-26-01
Monday, 01 July 2013 02:26 PM
Newsmax Media, Inc.

Sign up for Newsmax’s Daily Newsletter

Receive breaking news and original analysis - sent right to your inbox.

(Optional for Local News)
Privacy: We never share your email address.
Join the Newsmax Community
Read and Post Comments
Please review Community Guidelines before posting a comment.
 
You May Also Like
Get Newsmax Text Alerts
TOP

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved
NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved